SMTI News & Events

Sanara MedTech announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX Surgical Powder in the Journal of Medical Economics. The study estimated the cost-effectiveness of adding CellerateRX as an adjunct to the standard of care for reducing postoperative complications in high-risk spinal surgery patients. The researchers found that the group treated with CellerateRX exhibited a dominant cost-effectiveness profile compared to the group treated with the standard of care alone. Specifically, the CellerateRX treatment arm generated $3,852 in cost savings and a 0.007 QALY gain per patient, yielding a net monetary benefit of $4,542. The primary contributors to cost savings were the avoidance of hospital readmissions and surgical revision procedures, which conservatively accounted for $2,238 and $835 of the total cost reductions, respectively.

Net revenue for the fourth quarter of 2025 is expected to be in the range of $27.2 million to $27.7 million, an increase of approximately 3% to 5%, compared to $26.3 million in the fourth quarter of 2024. "Our team delivered strong performance in 2025, culminating in preliminary net revenue of approximately $103 million, an increase of approximately 19% year-over-year," stated Seth Yon, Sanara's President and Chief Executive Officer. "In the fourth quarter of 2025, our preliminary net revenue increased in the range of 11% to 13% year-over-year, excluding approximately $1.8 million of BIASURGE sales in the prior year period, consistent with the range of expectations shared on our Q3 earnings call. Operationally, we made important progress across multiple areas during the fourth quarter. Importantly, we secured a new contract with Vizient, Inc. - the largest group purchasing organization in the U.S. - which significantly expands access to BIASURGE at contracted pricing and pre-negotiated terms. In addition, we enhanced our sales and distribution network, while also working to expand our product portfolio through our initiatives with BMI related to OsStic."

Stock futures were mixed following a mixed trading day as investors took profits and shifted focus to this week's economic data. Meanwhile, comments from President Trump that the 2027 military budget should be higher caused multiple defense stocks to surge after-hours.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Constellation Brandsup 1.8%ALSO HIGHER -Globus Medicalup 9.5% after providing guidance for Q4, FY25, and FY26Gapup 4.1% after UBS upgraded the stock to Buy from NeutralSanara MedTechup 1.3% after receiving a Biasurge contract from VizientHIGHER AFTER TRUMP COMMENTS ON MILITARY BUDGET -AeroVironmentup 8.6%Lockheed Martinup 6.4%Northrop Grummanup 5.7%L3Harrisup 5.3%General Dynamicsup 4.3%Huntington Ingallsup 3.7%RTX Corp.up 3.5%LOWER AFTER EARNINGS -Resources Connectiondown 11.6%Franklin Coveydown 10.2%Jefferies Financialdown 2.7%ALSO LOWER -Immuneeringdown 21.9% after reporting overall survival and safety data from its atebimetinib trialPhathom Pharmaceuticalsdown 12.1% after announcing a common stock offering and raising its FY25 revenue guidance

Sanara MedTech announced that its Biasurge product has received a technology contract from Vizient. "We are pleased to see Vizient award this new Innovative Technology contract for Biasurge based on the recommendation of hospital experts, reflecting the differentiated nature of this surgical technology," said Seth Yon, Sanara MedTech's president and CEO. "Biasurge's no-rinse irrigation solution enables surgeons to cleanse the wound bed more efficiently than with saline alone, and its antimicrobial preservative provides broad-spectrum antimicrobial effectiveness in the irrigation solution."